Viral vectors in cancer immunotherapy
Author(s)
Bibliographic Information
Viral vectors in cancer immunotherapy
(International review of cell and molecular biology / series editors, Lorenzo Galluzzi, v. 379)
Academic Press, an imprint of Elsevier, 2023
Available at 2 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references
Description and Table of Contents
Description
Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more.
The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies.
Table of Contents
1. Viral Vectors Engineered for Gene Therapy
Kenneth Lundstrom
2. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity
Noelia Silva-Pilipich, Angela Covo-Vergara, Lucia Vanrell, and Cristian Smerdou
3. Armored modified vaccinia Ankara in cancer immunotherapy
Cigdem Atay, Jose Medina-Echeverz, Hubertus Hochrein, Mark Suter, and Maria Hinterberger
4. Alphaviruses in Cancer Immunotherapy
Kenneth Lundstrom
5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success
Irati Hervas-Corpion and Marta M. Alonso
6. Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies
Mario Sousa-Pimenta, Angelo Martins, and Vera Machado
7. Oncolytic virotherapy in lung cancer
Estanislao Nistal-Villan, Sergio Rius-Rocabert, and Francisco Llinares-Pinel
8. Rational selection of an ideal oncolytic virus to address current limitations in clinical translation
Rupsa Basu and Chad M. Moles
by "Nielsen BookData"